Business Case Creation for a US-Based Novel Blood Glucose Monitoring Company
“CGM with infusion pump is very expensive for patients to buy. In India, hardly a few patients have CGM - let alone infusion pumps. Now with newer technology I hope cost comes down and more patients have access to continuous monitoring. In Metropolitan cities around 5 % of the diabetic population would buy SMBG monitors.
- November 18, 2015
- Posted by: Team EMeRG
- Category: APAC / ASEAN, BY BUSINESS CHALLENGES, BY MEDICAL TECHNOLOGIES, Diabetes Management, Market Entry Assessment, NPI Research, Pricing Research